Modulation of Anti-tumor T Cell Responses in Cancer Patients Treated by Concomitant Radiochemotherapy
The aim of this study is to evaluate modulation of anti-tumor T cell responses in cancer patients treated by concomitant radiochemotherapy (i-RTCT)
Lung Cancer|Head and Neck Cancer
OTHER: Biological samples
tumor antigen specific T-cell responses, tumor antigen specific T-cell responses, up to 12 months after the end of radiochemotherapy
monitoring of immune checkpoints, immune cell death, immune suppressive cells and T-cell polarisation, monitoring of immune checkpoints, immune cell death, immune suppressive cells and T-cell polarisation, up to 12 months after the end of radiochemotherapy|Progression free survival, time interval between the date of initiation of treatment and the date of first progression (local, remote \[extent of the disease by RECIST v1.1\] second cancer) or death from any cause, date of first progression of the disease (within 2 year after the initiation of the treatment)]|overall survival, time between the date of initiation of treatment and the date of death from any cause, date of death from any cause (within 2 years after the initiation of the treatment)|Quality of life related to health measured by EORTC-QLQC30, Quality of life related to health measured by EORTC-QLQC30, from the inclusion to patient death, up to 1 year
The aim of this study is to evaluate modulation of anti-tumor T cell responses in cancer patients treated by concomitant radiochemotherapy (i-RTCT)